The FDA has rejected Sanofi's application seeking approval of tolebrutinib to treat certain forms of MS in its present form.
The festive period brought some unwanted post for both Sanofi and Corcept Therapeutics in the form of FDA rejections for the ...
Two new sub-types of multiple sclerosis (MS) were discovered by researchers from Queen Square Analytics and University ...
Scientists have used AI to identify two novel subtypes of multiple sclerosis (MS), which could offer new, targeted treatments ...
By analysing MRI scans and a simple blood test from hundreds of patients, researchers identified patterns that reveal how ...
Sanofi (NASDAQ:SNY) said on December 15 that a US regulatory decision for its experimental multiple sclerosis drug will be ...
Exclusive: Scientists uncovered biological strands using artificial intelligence and hope discovery will revolutionise treatment ...
Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...
That scuppered Sanofi's plans for filing tolebrutinib in PPMS, and the FDA has now slammed the brakes on its efforts to get ...
Findings showed the study met its primary endpoint demonstrating a reduction in disability accumulation with tolebrutinib compared with placebo. Tolebrutinib was found to delay disability progression ...
The HERCULES study of tolebrutinib is the first and only to show reduced confirmed disability progression at 6 months in nonrelapsing secondary progressive multiple sclerosis (MS). The HERCULES ...
The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application for tolebrutinib for the treatment of non-relapsing secondary progressive multiple sclerosis (nrSPMS).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback